News

In about 3% to 5% of patients with NSCLC MET alterations are presented that can drastically change a patient's prognosis. Now, an investigational MET inhibitor called tepotinib was granted a breakthrough designation by the FDA, and it may prove beneficial for patients in this space.

Targeted therapies for patients with EGFR-mutated and HER2-positive NSCLC have yet to see widespread success, but these 3 novel therapies, presented at the 2019 World Conference on Lung Cancer, show promise for this patient population.

The FDA has granted a fast track designation to the KRAS inhibitor AMG 510 for the treatment of patients who received prior treatment with KRAS G12C-mutated NSCLC.

Treating patients with multiple myeloma can be difficult, but in the past several months there have been a large number of promising updates to potential new combinations of treatment.

Patients with METex14-Mutated NSCLC potentially have a new first-line treatment to look towards as Capmatinib has been granted a breakthrough designation by the FDA.

One expert discusses how immunotherapy is changing the treatment – and adverse event – landscape in oncology.

When one of your patients is diagnosed with gastrointestinal cancer, it can be difficult for them to cope with their diagnosis. However, as their Oncology nurse, you can help guide them to reliable patient resources on stomach cancer, like Debbie’s Dream Foundation.

Here are the top 5 Oncology Nursing News stories for August 2019.

A certified genetic counselor discusses the role of genetic testing in gastrointestinal cancers.

Patients are getting a ton of information from outside sources and advertisements about new immunotherapy agents. It is crucial that providers offer them the key facts that they need.

This week, Johnson & Johnson was ordered to pay $572 million for contributing to the opioid crisis in the state of Oklahoma.

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer (mCRC) whose tumors are microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR)—a population with a historically poor prognosis, said Heinz-Josef Lenz, MD, FACP.

Before considering intraperitoneal chemotherapy, or dose-dense chemotherapy, for newly diagnosed patients with advanced ovarian cancer, it's not vital to first determine whether the patient is medically fit for these treatments.

Chemotherapy is the foundation of treatment for patients with recurrent ovarian cancer, but according to Madeleine B. Courtney Brooks, MD, MPH, conversations regarding the potential for secondary debulking and use of bevacizumab (Avastin) may also be warranted.

While the US Preventative Services Task Force expanded their recommendations of who should be tested for BRCA mutations, there are still issues left unaddressed, according to one expert.

The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), according to Astellas Pharma Inc. and Pfizer Inc., the codevelopers of the androgen receptor inhibitor.

There are multiple steps nurses must take to prevent and manage pulmonary toxicities in patients taking immunotherapy.

Two different randomized clinical trials not only validated the value of annual lung cancer screening in patients, but also can open the doors for vital smoking cessation talks.

The Centers for Medicare and Medicaid Services (CMS) announced that it will cover chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Save the date! We invite you to join Oncology Nursing News for an #OncNurseConnect Tweet Chat on Wednesday, August 21.

This is the first approval for this patient population in nearly a decade.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

Oncology nurses can make the world of a difference when it comes to patient care, and it is crucial that they work together with other members of the treatment team to ensure the best outcomes, according to Sally Werner, MSHA, BSN, RN, senior vice president, affiliate relations at Cancer Support Community.

Workplace violence for healthcare workers – including nurses – is on the rise. Here’s what nurses need to know about the hot-button topic.

Hair, skin, or nail reactions commonly occur in patients treated with immunotherapy and targeted therapy for cancer.

PARP inhibitors have shown success in breast and ovarian cancer, and now they may be moving into the pancreatic cancer paradigm, too.

Robert M. Wenham, MD discusses evolving strategies in the ovarian cancer space.

The Food and Drug Administration (FDA) approved pexidartinib for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT).

About 25% of healthcare-related infections come from catheters, but there are steps nurses can take to mitigate this problem.

Here are the top 5 Oncology Nursing News stories for July 2019.